EyePoint Pharmaceuticals (EYPT) Reports First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for Treatment of Wet AMD
Go back to EyePoint Pharmaceuticals (EYPT) Reports First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for Treatment of Wet AMD(NASDAQ: EYPT) | Delayed: 17.65 +0.15 (0.86%) | |||||
---|---|---|---|---|---|---|
Previous Close | $17.50 | 52 Week High | $ | |||
Open | $17.67 | 52 Week Low | $ | |||
Day High | $17.80 | P/E | N/A | |||
Day Low | $16.71 | EPS | $ | |||
Volume | 1,548,436 |